Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation

^a Department of Neurosurgery, Brain Tumor/Neuro-Oncology Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
^b Department of Neurosciences, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
^c Department of Molecular Biology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
^d Department of Microbiology, The Tokyo Metropolitan Institute of Medical Science, Tokyo 113, Japan
^e Department of Hematology, Research Institute, International Medical Center of Japan, Tokyo 162, Japan
^f Geron Corporation, 200 Constitution Drive, Menlo Park, California 94025, USA

Telomerase, the enzyme that elongates telomeric DNA (TTAGGG)_n, may be involved in cellular immortality and oncogenesis. To investigate the effect of inhibition of telomerase on tumor cells, we transfected the antisense vector against the human telomerase RNA into human malignant glioma cells exhibiting telomerase activity. After 30 doublings, some subpopulations of transfectants expressed a high level of interleukin-1ß-converting enzyme (ICE)² protein and underwent apoptosis. In contrast, other subpopulations also showed enhanced ICE protein but escaped from apoptotic crisis and continued to grow, although their DNA synthesis, invasive ability, and tumorigenicity in nude mice were significantly reduced. Surviving cells demonstrated increased expression of glial fibrillary acidic protein and decreased motility, consistent with a more differentiated state. These cells also contained enhanced expression of the cyclin-dependent kinase inhibitors (CDKIs) p21 and p27. Treatment of surviving nonapoptotic cells with antisense oligonucleotides against p27, but not p21, induced apoptotic cell death, suggesting that p27 may have protected differentiating glioma cells from apoptosis. These data show that treatment with antisense telomerase inhibits telomerase activity and subsequently induces either apoptosis or differentiation. Regulation of these two distinct pathways may be dependent on the expression of ICE or CDKIs.—Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G. H., Ishizaka, Y., Liu, J., Haqqi, T., Nishiyama, A., Villeponteau, B., Cowell, J. K., Barna, B. P. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation FASEB J. 12, 801–811 (1998)

Key Words: ICE • p27 • CDKI • tumor cells • tumorigenicity • oglionucleotide

This article has been cited by other articles:

				M NATARAJAN, S MOHAN, R KONOPINSKI, R A OTTO, and T S HERMAN Induced telomerase activity in primary aortic endothelial cells by low-LET {gamma}-radiation is mediated through NF-{kappa}B activation Br. J. Radiol., September 1, 2008; 81(969): 711 - 720. [Abstract] [Full Text] [PDF]

				A. E. Schwob, L. J. Nguyen, and K. F. Meiri Immortalization of Neural Precursors When Telomerase Is Overexpressed in Embryonal Carcinomas and Stem Cells Mol. Biol. Cell, April 1, 2008; 19(4): 1548 - 1560. [Abstract] [Full Text] [PDF]

				M. Doshida, M. Ohmichi, S. Tsutsumi, J. Kawagoe, T. Takahashi, B. Du, A. Mori-Abe, T. Ohta, M. Saitoh-Sekiguchi, K. Takahashi, et al. Raloxifene Increases Proliferation and Up-regulates Telomerase Activity in Human Umbilical Vein Endothelial Cells J. Biol. Chem., August 25, 2006; 281(34): 24270 - 24278. [Abstract] [Full Text] [PDF]

				S. L. Schissel and M. D. Layne Telomerase, myofibroblasts, and pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 520 - 522. [Full Text] [PDF]

				J. Wang, H. Feng, X.-Q. Huang, H. Xiang, Y.-W. Mao, J.-P. Liu, Q. Yan, W.-B. Liu, Y. Liu, M. Deng, et al. Human Telomerase Reverse Transcriptase Immortalizes Bovine Lens Epithelial Cells and Suppresses Differentiation through Regulation of the ERK Signaling Pathway J. Biol. Chem., June 17, 2005; 280(24): 22776 - 22787. [Abstract] [Full Text] [PDF]

				M. A. Shammas, R. J. Shmookler Reis, M. Akiyama, H. Koley, D. Chauhan, T. Hideshima, R. K. Goyal, L. H. Hurley, K. C. Anderson, and N. C. Munshi Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma Mol. Cancer Ther., September 1, 2003; 2(9): 825 - 833. [Abstract] [Full Text] [PDF]

				R. Villa, M. Folini, C. D. Porta, A. Valentini, M. Pennati, M. G. Daidone, and N. Zaffaroni Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells Carcinogenesis, May 1, 2003; 24(5): 851 - 859. [Abstract] [Full Text] [PDF]

				S. Roy, S. Khanna, A. A. Bickerstaff, S. V. Subramanian, M. Atalay, M. Bierl, S. Pendyala, D. Levy, N. Sharma, M. Venojarvi, et al. Oxygen Sensing by Primary Cardiac Fibroblasts: A Key Role of p21Waf1/Cip1/Sdi1 Circ. Res., February 21, 2003; 92(3): 264 - 271. [Abstract] [Full Text] [PDF]

				Y. Mo, Y. Gan, S. Song, J. Johnston, X. Xiao, M. G. Wientjes, and J. L-S. Au Simultaneous Targeting of Telomeres and Telomerase as a Cancer Therapeutic Approach Cancer Res., February 1, 2003; 63(3): 579 - 585. [Abstract] [Full Text] [PDF]

				W. Fu, C. Lu, and M. P. Mattson Telomerase Mediates the Cell Survival-Promoting Actions of Brain-Derived Neurotrophic Factor and Secreted Amyloid Precursor Protein in Developing Hippocampal Neurons J. Neurosci., December 15, 2002; 22(24): 10710 - 10719. [Abstract] [Full Text] [PDF]

				J. Chen, S. V. Brodsky, D. M. Goligorsky, D. J. Hampel, H. Li, S. S. Gross, and M. S. Goligorsky Glycated Collagen I Induces Premature Senescence-Like Phenotypic Changes in Endothelial Cells Circ. Res., June 28, 2002; 90(12): 1290 - 1298. [Abstract] [Full Text] [PDF]

				J.-L. Mergny, J.-F. Riou, P. Mailliet, M.-P. Teulade-Fichou, and E. Gilson Natural and pharmacological regulation of telomerase Nucleic Acids Res., February 15, 2002; 30(4): 839 - 865. [Abstract] [Full Text] [PDF]

				T. Komata, Y. Kondo, T. Kanzawa, S. Hirohata, S. Koga, H. Sumiyoshi, S. M. Srinivasula, B. P. Barna, I. M. Germano, M. Takakura, et al. Treatment of Malignant Glioma Cells with the Transfer of Constitutively Active Caspase-6 Using the Human Telomerase Catalytic Subunit (Human Telomerase Reverse Transcriptase) Gene Promoter Cancer Res., August 1, 2001; 61(15): 5796 - 5802. [Abstract] [Full Text] [PDF]

				S. Mukai, Y. Kondo, S. Koga, T. Komata, B. P. Barna, and S. Kondo 2-5A Antisense Telomerase RNA Therapy for Intracranial Malignant Gliomas Cancer Res., August 1, 2000; 60(16): 4461 - 4467. [Abstract] [Full Text]

				Y. Kudo, T. Takata, I. Ogawa, T. Kaneda, S. Sato, T. Takekoshi, M. Zhao, M. Miyauchi, and H. Nikai p27Kip1 Accumulation by Inhibition of Proteasome Function Induces Apoptosis in Oral Squamous Cell Carcinoma Cells Clin. Cancer Res., March 1, 2000; 6(3): 916 - 923. [Abstract] [Full Text]

				S. Y. Rha, E. Izbicka, R. Lawrence, K. Davidson, D. Sun, M. P. Moyer, G. D. Roodman, L. Hurley, and D. Von Hoff Effect of Telomere and Telomerase Interactive Agents on Human Tumor and Normal Cell Lines Clin. Cancer Res., March 1, 2000; 6(3): 987 - 993. [Abstract] [Full Text]

				J.-P. LIU Studies of the molecular mechanisms in the regulation of telomerase activity FASEB J, December 1, 1999; 13(15): 2091 - 2104. [Abstract] [Full Text]

				X. Zhang, V. Mar, W. Zhou, L. Harrington, and M. O. Robinson Telomere shortening and apoptosis in telomerase-inhibited human tumor cells Genes & Dev., September 15, 1999; 13(18): 2388 - 2399. [Abstract] [Full Text]

				J. Yang, E. Chang, A. M. Cherry, C. D. Bangs, Y. Oei, A. Bodnar, A. Bronstein, C.-P. Chiu, and G. S. Herron Human Endothelial Cell Life Extension by Telomerase Expression J. Biol. Chem., September 10, 1999; 274(37): 26141 - 26148. [Abstract] [Full Text] [PDF]

				J. S. Dome, S. Chung, T. Bergemann, C. B. Umbricht, M. Saji, L. A. Carey, P. E. Grundy, E. J. Perlman, N. E. Breslow, and S. Sukumar High Telomerase Reverse Transcriptase (hTERT) Messenger RNA Level Correlates with Tumor Recurrence in Patients with Favorable Histology Wilms' Tumor Cancer Res., September 1, 1999; 59(17): 4301 - 4307. [Abstract] [Full Text] [PDF]

				J. Sarvesvaran, J. J. Going, R. Milroy, S. B. Kaye, and W.N. Keith Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis, August 1, 1999; 20(8): 1649 - 1652. [Abstract] [Full Text] [PDF]

				P. A. Hershberger, R. A. Modzelewski, Z. R. Shurin, R. M. Rueger, D. L. Trump, and C. S. Johnson 1,25-Dihydroxycholecalciferol (1,25-D3) Inhibits the Growth of Squamous Cell Carcinoma and Down-Modulates p21Waf1/Cip1 in Vitro and in Vivo Cancer Res., June 1, 1999; 59(11): 2644 - 2649. [Abstract] [Full Text] [PDF]

				T. Minamino and S. Kourembanas Mechanisms of Telomerase Induction During Vascular Smooth Muscle Cell Proliferation Circ. Res., August 3, 2001; 89(3): 237 - 243. [Abstract] [Full Text] [PDF]